Abivax has presented new preclinical and clinical data for obefazimod [...]
Long-term VIVID-2 data show more than 90% of patients with [...]
The Scottish Medicines Consortium (SMC) has accepted guselkumab for the [...]
MRM Health, a clinical stage biopharmaceutical company developing microbiome-based therapeutics, [...]
NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure
Mirikizumab is now recommended by NICE for routine NHS use [...]
The National Institute for Health and Care Excellence (NICE) has [...]
A new collaboration aims to tackle the toughest challenges in [...]